University of Maryland Greenbaum Comprehensive Cancer Center Among Top Sites to Enroll Patients in National Clinical Trials

April 25, 2019

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has been recognized by NRG Oncology, a major research group within the National Cancer Institute (NCI) National Clinical Trials Network, as one of its top “main member” sites worldwide to enroll patients in clinical trials in 2018.

Many of these multi-institutional trials involve radiation therapy, and UMGCCC’s No. 6 ranking on NRG Oncology’s list of “top accruing main member sites” is due to the efforts of physicians in the University of Maryland Department of Radiation Oncology, led by William F. Regine, MD, FACR, FACRO. Patients recruited to take part in clinical trials for a variety of cancers were not only from UMGCCC, but also the department’s community-based practices and affiliated cancer centers within the University of Maryland Cancer Network.

Continue reading the full news story at www.umms.org/umgccc.